YuanSheng Ventures
元生创投
YuanSheng Ventures (元生创投) is a Chinese venture capital fund active in healthcare and deep-tech investing, with a particular concentration on innovative drug development and medical technology. It has served as lead investor in several notable rounds, including neoX Biotech's Series A+ in 2021 , Pulnovo Medical's funding round in 2022 , and Penglai Data's A+ round in 2022 , while also participating as a co-investor alongside firms such as BlueRun Ventures and Legend Capital in companies like AllinkBio and Shize Biotech . The fund's activity spans from at least 2021 through 2024-2025 per available records, though elsewhere's corpus does not cover its founding details, team, or assets under management.
AI-generated — may contain errors, please verify.